L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

Summary

L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells. The goal of this study is to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of L218CAR19 in patients with B-cell lymphomas who have received at least two lines of systemic treatment.

Timeline

Start

2024-06-01

Primary completion

2025-12-31

Completion

2026-06-30

Drugs

Indications